LYEL
Lyell Immunopharma, Inc.
-0.02 (-0.14%)10.76USD40.4K成交股數264M市值–本益比(近四季)9765.8股價營收比-50.0%營收年增(近四季)2026-11-06下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 4K-50% | 2K-71% | 6K-82% | 15K+15% | 8K+167% | 7K-46% | 34K+36% | 13K-52% | 3K | 13K | 25K | 27K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 39.5M | 36.6M | 52.2M | 28.2M | 34.9M | 43.4M | 39.5M | 40.3M | 43.2M | 47.0M | 43.8M | 47.5M |
| 銷售管理費用 | 9.6M | 9.6M | 10.6M | 10.7M | 9.8M | 14.0M | 11.8M | 12.3M | 13.5M | 13.2M | 15.5M | 19.0M |
| 營業利益 | −47.3M+0% | −44.3M-23% | −128M+153% | −37.3M-28% | −47.1M-15% | −57.4M-4% | −50.5M-14% | −51.5M-22% | −55.6M | −59.5M | −59.0M | −65.9M |
| 營業利益率 | -1,183,425.0% | -2,213,050.0% | -2,127,400.0% | -248,353.3% | -589,250.0% | -819,528.6% | -148,544.1% | -396,369.2% | -1,852,500.0% | -457,753.8% | -236,156.0% | -244,092.6% |
| 稅後淨利 | −44.8M+5% | −24.2M-54% | −141M+216% | −38.8M-15% | −42.7M-30% | −52.2M-1% | −44.6M-12% | −45.8M-28% | −60.7M | −52.9M | −50.9M | −63.9M |
| 淨利率 | -1,118,875.0% | -1,207,650.0% | -2,345,383.3% | -258,973.3% | -533,550.0% | -745,642.9% | -131,126.5% | -352,376.9% | -2,022,233.3% | -407,153.8% | -203,412.0% | -236,629.6% |
| 稀釋 EPS | -1.92-34% | -1.10-69% | -7.50+116% | -2.13-41% | -2.89+1104% | -3.54-80% | -3.48+1640% | -3.59+1281% | -0.24 | -17.97 | -0.20 | -0.26 |
| 稀釋股數 | 23.4M | 21.9M | 17.1M | 18.3M | 14.8M | 14.8M | 12.8M | 12.8M | 254M | 12.5M | 251M | 250M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 73.0M | 90.8M | 60.2M | 124M | 98.8M | 120M | 100M | 133M | 126M | 146M | 286M | 224M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 311M | 351M | 340M | 408M | 385M | 430M | 619M | 654M | 694M | 750M | 795M | 835M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 77.3M | 77.0M | 91.9M | 78.8M | 86.5M | 93.3M | 88.5M | 87.6M | 91.1M | 95.1M | 97.4M | 98.5M |
| 股東權益 | 234M | 274M | 248M | 329M | 299M | 337M | 531M | 567M | 603M | 655M | 698M | 737M |
| 負債比 | 24.9% | 21.9% | 27.0% | 19.3% | 22.4% | 21.7% | 14.3% | 13.4% | 13.1% | 12.7% | 12.3% | 11.8% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −38.5M-30% | – | – | – | −54.7M | – | – | −42.0M | – | – | – |
| 資本支出 | – | 89K | – | – | – | 246K | – | – | 30K | – | – | – |
| 自由現金流 | – | −38.6M-30% | – | – | – | −55.0M | – | – | −42.0M | – | – | – |
| 折舊攤銷 | – | 2.3M | – | – | – | 3.4M | – | – | 5.0M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -1,929,950.0% | – | – | – | -785,485.7% | – | – | -1,401,533.3% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 36K
| Reportable | 36K | 100.0% | -41.0% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 36K | -41.0% | −274M | -762,355.6% | -16.06 | −151M |
| FY2024 | 61K | -53.1% | −343M | -562,285.2% | -26.23 | −163M |
| FY2023 | 130K | -99.8% | −235M | -180,486.2% | -18.70 | −166M |
| FY2022 | 84.7M | +695.1% | −183M | -216.2% | -0.74 | −194M |
| FY2021 | 10.7M | +37.3% | −250M | -2,349.5% | -1.84 | −192M |
| FY2020 | 7.8M | +1080.5% | −204M | -2,636.3% | -15.69 | −212M |
| FY2019 | 657K | – | −129M | -19,692.1% | -24.04 | 23.4M |